Schonfeld Strategic Advisors’s Relmada Therapeutics RLMD Stock Holding History

Schonfeld Strategic Advisors’s Portfolio RLMD Stock Details RLMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$162K	Buy	23,247 +10,031	+76%	+$47.5K	﹤0.01%	1797
2025 Q4	$63.8K	Buy	+13,216	New	+$44.3K	﹤0.01%	1866
2023 Q4	–	Sell	-109,310	Closed	-$328K	–	2163
2023 Q3	$328K	Buy	+109,310	New	+$325K	﹤0.01%	1312
2023 Q1	–	Sell	-75,300	Closed	-$263K	–	2562
2022 Q4	$263K	Sell	75,300 -75,200	-50%	-$660K	﹤0.01%	1856
2022 Q3	$5.57M	Buy	+150,500	New	+$4.17M	0.05%	492
2022 Q1	–	Sell	-54,800	Closed	-$1.24M	–	2875
2021 Q4	$1.24M	Sell	54,800 -58,138	-51%	-$1.29M	0.01%	837
2021 Q3	$2.96M	Buy	112,938 +55,177	+96%	+$1.48M	0.03%	578
2021 Q2	$1.85M	Buy	57,761 +3,260	+6%	+$113K	0.02%	740
2021 Q1	$1.92M	Buy	+54,501	New	+$1.91M	0.02%	675

Other funds holding RLMD

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $273M AUM

SSC

Spruce Street Capital New York $416M AUM

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Schonfeld Strategic Advisors's RLMD Position: Q1 2026 in Review

Schonfeld Strategic Advisors increased its Relmada Therapeutics (RLMD) stake by 76% in Q1 2026, buying an estimated $47.5K and bringing the position to 23,247 shares worth $162K. The position accounts for ﹤0.01% of the portfolio, ranked #1797.

Schonfeld Strategic Advisors first reported a position in RLMD in Q1 2021 and has held it in 9 quarters since. The position peaked at $5.57M in Q3 2022. 103 funds tracked by Wall St. Rank hold RLMD as of Q1 2026.

Schonfeld Strategic Advisors held 23,247 shares of Relmada Therapeutics worth $162K as of Q1 2026.
Schonfeld Strategic Advisors bought 10,031 Relmada Therapeutics shares in Q1 2026, an estimated $47.5K.
Relmada Therapeutics made up ﹤0.01% of Schonfeld Strategic Advisors's portfolio in Q1 2026, its #1797 holding.
Schonfeld Strategic Advisors first reported a position in Relmada Therapeutics in Q1 2021 and has held it in 9 quarters since.
Schonfeld Strategic Advisors's Relmada Therapeutics position peaked at $5.57M in Q3 2022.
103 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q1 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2026, filed 15 May 2026.